Gabriel Ozorowski

Jun 14, 2024 | nature.com | Ivy Phung |Olivia K. Swanson |Chang-Chun D. Lee |Ester Marina-Zárate |Gabriel Ozorowski |Kimmo Rantalainen | +28 more

Correction to: Nature Immunology https://doi.org/10.1038/s41590-024-01833-w, published online 30 May 2024In the version of the article initially published, Steven Schultze’s surname appeared incorrectly (as Schulze) and has now been amended in the HTML and PDF versions of the article.

May 30, 2024 | nature.com | Ivy Phung |Olivia K. Swanson |Chang-Chun D. Lee |Ester Marina-Zárate |Gabriel Ozorowski |Kimmo Rantalainen | +28 more

AbstractA key barrier to the development of vaccines that induce broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV) and other viruses of high antigenic diversity is the design of priming immunogens that induce rare bnAb-precursor B cells.

Nov 4, 2023 | nature.com | Ivy Phung |Kristen A. Rodrigues |Ester Marina-Zárate |Bapi Pahar |Wen-Hsin Lee |Pyone P. Aye | +13 more

AbstractAdjuvants and antigen delivery kinetics can profoundly influence B cell responses and should be critically considered in rational vaccine design, particularly for difficult neutralizing antibody targets such as human immunodeficiency virus (HIV). Antigen kinetics can change depending on the delivery method.

Jan 30, 2023 | nature.com | Henry Sutton |Chris Cottrell |Ivy Phung |Gabriel Ozorowski |Jonathan Torres |Wen-Hsin Lee | +10 more

Author notesThese authors contributed equally: Jeong Hyun Lee, Henry J. SuttonAuthors and AffiliationsCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USAJeong Hyun Lee, Henry J. Sutton, Ivy Phung, Catherine Nakao, Kimberly M. Cirelli & Shane CrottyConsortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USAJeong Hyun Lee, Henry J. Sutton, Christopher A.